APR 21 2027
Belite Bio — tinlarebant $BLTE
for Stargardt disease type 1 (juvenile macular dystrophy)
Accepted JUN 12 2026.
About
Stargardt disease is an inherited retinal disorder that causes progressive macular degeneration and vision loss, often beginning in childhood. Tinlarebant is an oral drug that blocks retinol-binding protein 4 (RBP4), a key carrier of vitamin A to the eye. By limiting the supply of vitamin A to the retina, the drug may slow the toxic buildup of waste products that drive vision loss in these patients.
Pivotal trial
The primary objective of this trial is to assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on tinlarebant
- Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases - Yahoo Finance
- Belite Bio presents additional Phase 3 trial data for tinlarebant - Investing.com
- Will Tinlarebant’s First-in-Disease Data and FDA Filing Change Belite Bio’s (BLTE) Narrative? - simplywall.st
- Tinlarebant retinal marker stayed stable or fell ~2%; placebo rose 20% - Stock Titan
- Belite Bio completes FDA filing for tinlarebant in Stargardt disease type 1 - Bitget
Sponsor Watch — recent news on Belite Bio
- Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases
- Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
- Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease
- Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
- Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1